Find News

Filter articles

Applied Filters

Showing 1021 to 1030 of 1058 results

Glenmark confirms Vimpat challenge


Pharmaceutical company Glenmark Generics has confirmed that it has filed ANDAs with the US FDA to market generic versions of epilepsy drug Vimpat.

Australian bid for OxyContin generic dismissed

Australia12-07-2013Legal developments

The Federal Court of Australia has dismissed Spirit Pharmaceutical’s bid to introduce a generic version of painkiller OxyContin.

UCB challenges Teva generic drug application


Belgian pharmaceutical company UCB SA has sued drug-maker Teva Pharmaceutical Industries to stop it manufacturing a generic version of epilepsy drug Vimpat.

Merck wins injunction in sitagliptin patent row


Pharmaceutical company Merck has secured a preliminary injunction against Indian drug company Aprica after it tried to market generic versions of the branded diabetes drug Januvia.

Generics swoop as Viagra patent expires


Global drug companies Actavis and Teva both launched generic versions of Viagra immediately after its patent expired in several European countries last week.

Federal Circuit holds Novo Nordisk patent invalid

US21-06-2013Legal developments

The US Court of Appeals for the Federal Circuit concluded on June 18 that Novo Nordisk’s patent covering diabetes treatment repaglinide is invalid.

European Commission targets alleged ‘pay-for-delay’ with pharma fines


The European Commission’s competition directorate has levied fines totalling €146 million ($195 million) against originator pharmaceutical company Lundbeck and several producers of generics drugs.

US Supreme Court backs ‘rule-of-reason’ for pay-for-delay


A majority of the US Supreme Court has ruled that the US Federal Trade Commission should be able to challenge so-called ‘pay-for-delay’ patent litigation settlements on antitrust grounds.

Teva and Sun stung by $2 billion settlement


Generic drug-makers Teva Pharmaceutical and Sun Pharmaceutical have agreed to pay a combined $2.15 billion to settle a patent infringement case over Pfizer’s heartburn drug Protonix.

IPAB sets aside Sutent patent rejection


India’s Intellectual Property Appellate Board has set aside a decision revoking a Pfizer-licensed patent directed to cancer drug Sutent.

Showing 1021 to 1030 of 1058 results